Oramed Pharmaceuticals (ORMP) vs Veraxa Biotech (VRXA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Oramed Pharmaceuticals (ORMP) has outperformed Veraxa Biotech (VRXA) over the past year, gaining 76.2% versus a loss of 88.5%. Oramed Pharmaceuticals is the larger company by market cap ($174.7 million vs $154.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ORMP | VRXA |
|---|---|---|
| Share price | $4.20 | $1.09 |
| Market cap | $174.71M | $154.13M |
| 1-day change | -3.89% | -9.17% |
| YTD return | +53.33% | -88.75% |
| 1-year return | +76.21% | -88.53% |
| 5-year return | -80.19% | — |
| P/E ratio (TTM) | 1.02 | — |
| EPS (TTM) | $4.13 | $-0.57 |
| Dividend yield | 5.71% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.47 | $27.36 |
| 52-week low | $2.09 | $1.04 |
| Distance from 52-week high | -23.22% | -96.02% |
| Analyst consensus | none | — |
| Avg. price target upside | +66.67% | — |
| Average volume | 192.76K | 274.75K |
| Shares outstanding | 41.60M | 141.41M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ORMP has outperformed VRXA by 164.7 percentage points over the past year.
- Oramed Pharmaceuticals offers a meaningfully higher dividend yield (5.71% vs 0.00%).
About Oramed Pharmaceuticals
ORMP stock →Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.
Health Care · Biotechnology: Pharmaceutical Preparations
About Veraxa Biotech
VRXA stock →VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation.
Health Care · Biotechnology: Pharmaceutical Preparations
ORMP vs VRXA FAQ
Which is bigger, Oramed Pharmaceuticals or Veraxa Biotech?
Oramed Pharmaceuticals (ORMP) is larger, with a market capitalization of $174.71M compared with $154.13M for Veraxa Biotech (VRXA).
Which stock has performed better over the past year, ORMP or VRXA?
ORMP returned +76.21% over the past 12 months, compared with -88.53% for VRXA (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Oramed Pharmaceuticals or Veraxa Biotech?
Oramed Pharmaceuticals pays a dividend yielding 5.71%, while Veraxa Biotech does not currently pay a regular dividend.
Are Oramed Pharmaceuticals and Veraxa Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.